Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TIGAR small interfering RNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
TIGAR small interfering RNA is an RNA interference-based therapeutic approach designed to silence the expression of the TP53-induced glycolysis and apoptosis regulator (TIGAR) gene, also known as C12orf5. TIGAR is a p53-inducible protein that regulates glucose metabolism by lowering fructose-2,6-bisphosphate levels, thereby inhibiting glycolysis and promoting the pentose phosphate pathway to reduce oxidative stress. In various cancers, including ovarian cancer, TIGAR is frequently overexpressed and associated with poor prognosis. Silencing TIGAR via siRNA has been shown to sensitize cancer cells to poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib, by downregulating BRCA1 and the Fanconi anemia pathway, and by increasing cellular senescence through metabolic disruption.
- Other names
- TIGAR siRNAC12orf5 siRNAC-12orf5 siRNAC 12orf5 siRNATP53-induced glycolysis and apoptosis regulator siRNATP-53-induced glycolysis and apoptosis regulator siRNATP 53-induced glycolysis and apoptosis regulator siRNA
02
Targets
TIGAR (TP53-induced glycolysis and apoptosis regulator)
Beyond the preview
Go deeper on TIGAR small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TIGAR small interfering RNA.